Pacira_logo[1].JPG
EXPAREL Achieves Statistically Significant Reductions in Opioid Consumption and Pain Scores in Cesarean Section Patients
January 16, 2019 07:30 ET | Pacira Pharmaceuticals, Inc.
PARSIPPANY, N.J., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in...
Pacira_logo[1].JPG
New Retrospective Analysis Demonstrates Significant Reductions in Postsurgical Pain and Opioid Requirements with EXPAREL in Cesarean Section Patients
December 12, 2018 07:30 ET | Pacira Pharmaceuticals, Inc.
Results show incorporating transversus abdominis plane block with EXPAREL results in significantly improved patient functional recovery and hospital throughput Twelve percent of patients receiving...
Evolve BioSystems Partners With King’s College London to Resolve Gut Dysbiosis in C-Section Delivered Infants
February 01, 2018 08:00 ET | Evolve Biosystems
DAVIS, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Evolve BioSystems, Inc., a leader in advancing infant nutrition and health through restoration of the gut microbiome, announced today a collaboration...